Cerebral Vein Thrombosis
8
1
2
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
38%
3 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (8)
DOAC in Unusual Site Venous Thrombosis
Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
The Norwegian Cerebral Venous Thrombosis Study
Paroxysmal Nocturnal Hemoglobinuria in ESUS & ETUS
Multicenter Registry Study Of Cerebral Venous Thrombosis In China (RETAIN-CH)
Rivaroxaban vs. Warfarin in CVT Treatment
Venous Sinus Thrombosis : Clinical Picture and Outcome
Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism